HOPE Against Cancer Recurrence in HCC
This study is looking at a new way to prepare donor livers for transplant in patients with hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if a method called hypothermic oxygenated perfusion (HOPE) can reduce the chance of cancer coming back after a liver transplant. HOPE involves perfusing (flushing) the donor liver with an oxygen-rich fluid in a cold environment before it's transplanted. This is compared to the standard method of just cold storage. You might be able to join if you are an adult (over 18) and are scheduled for a liver transplant due to HCC, meeting specific tumor criteria. The study will measure how long patients live without their cancer returning, specifically at 24 months after transplant. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 220 participants. It compares two methods of preparing donor livers: hypothermic oxygenated perfusion (HOPE) and conventional cold storage.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, recurrence-free survival, will be measured at 24 months after the transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
HOPE Against Cancer Recurrence in HCC
At a glance
Conditions
NCT06717919
Where you'd take part
This study runs at 37 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
ASST Grande Ospedale Metropolitano Niguarda (Milan)
Milan, Italystudy coordinator listed
Not yet recruiting
Clarunis - University Digestive Health Care
Basel, Canton of Basel-City, Switzerlandstudy coordinator listed
Not yet recruiting
Cleveland Clinic
Cleveland, Ohiostudy coordinator listed
Not yet recruiting
Copenhagen University Hospital
Copenhagen, Denmarkstudy coordinator listed
Recruiting
Department of Surgical Oncology, Transplant Surgery and General Surgery, Medical University of Gdańsk
Gdansk, Polandstudy coordinator listed
Recruiting
Freeman Hospital (Newcastle)
Newcastle, United Kingdomstudy coordinator listed
Not yet recruiting
Gemelli University Hospital
Rome, Italystudy coordinator listed
Not yet recruiting
Hannover Medical School
Hanover, Germanystudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Recurrence free survival24 months
Post transplant HCC recurrence free survival, i.e. the time interval a patient is alive without HCC recurrence after transplantation, i.e., until either HCC recurrence is observed, or the patient dies from any cause.